AMRX Stock Analysis Today
Updated Nov 6, 2026 · trends, key levels, insider activity and news
Is AMRX bullish or bearish today?
Daily trend: Uptrend (confirmed) — turns down below $18.79
SEPT signal: Institutional Drive · Strong Bullish
Research grade: B+ · fair value $13.95 (+17.8%)
AMRX trend by timeframe
| Daily | Uptrend (confirmed) |
|---|---|
| 4 hour | Strong Bearish |
| 1 hour | Strong Bearish |
| 15 min | Strong Bearish |
| 5 min | Strong Bearish |
Trends are calculated from price structure and update during market hours.
AMRX support and resistance levels
Resistance (above)
$20.2812 touches
$21.6810 touches
$24.353 touches
Support (below)
$18.7919 touches
$17.617 touches
$16.5611 touches
Upside zones: $22.39 / $22.99 / $23.59
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 130-day net
—Hedge fund holders
258Latest AMRX news and filings
- EarningsBenzinga
Amneal Pharmaceuticals holds Q3 2026 earnings call
Amneal Pharmaceuticals discussed its third-quarter 2026 results on an earnings call. The headline gives no figures or details from the quarter.
- EarningsFiscal.ai
Amneal Pharmaceuticals releases Q3 2026 earnings, boosts yearly outlook
Amneal Pharmaceuticals published its quarterly numbers for the period ended in 2026 and lifted its forecast for the entire year. Specific figures were not included in the headline.
- GuidanceBenzinga
Amneal Pharmaceuticals lifts FY2026 adjusted EPS and sales guidance
Amneal Pharmaceuticals increased its fiscal 2026 adjusted earnings per share outlook to $1.04-$1.08 from $0.96-$1.06, and raised its sales forecast to $3.150B-$3.250B from $3.100B-$3.200B. Both new ranges sit above or near analyst estimates.
- EarningsBenzinga
Amneal third-quarter adjusted profit tops estimate at $0.26 per share
The drugmaker's quarterly adjusted earnings came in above analyst expectations. Revenue of $862.684 million also exceeded the $816.058 million forecast.
- AnalystGoldman Sachs
Goldman Sachs kept its Buy rating on Amneal (AMRX) and raised its price target to $24 from $21.
- ProductFiscal.ai
Amneal Pharmaceuticals boosts estradiol patch output as demand climbs
Amneal Pharmaceuticals is raising production of its estradiol patch in response to growing demand. The move expands supply of the company's hormone therapy product.
- LegalBenzinga
Trump administration drops opioid ban plan after kratom industry lobbying
The administration reversed course on a proposed opioid ban following lobbying from the kratom industry. The decision means kratom remains available under current rules.
- NewsFiscal.ai
Matthew Cascio leaves Amneal Pharmaceuticals to join Laxxon Medical
Matthew Cascio has departed Amneal Pharmaceuticals and moved to Laxxon Medical. The change involves a leadership shift at both companies.
Live AMRX chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is AMRX bullish or bearish today?
AMRX daily trend: Uptrend (confirmed) — turns down below $18.785. SEPT signal: Institutional Drive (Strong Bullish). Updated Nov 6, 2026.
What is AMRX's trend on each timeframe?
Daily: Uptrend (confirmed); 4 hour: Strong Bearish; 1 hour: Strong Bearish; 15 min: Strong Bearish; 5 min: Strong Bearish.
What are AMRX support and resistance levels?
Support: $18.79, $17.61, $16.56. Resistance: $20.28, $21.68, $24.35. Last price $19.45.
Are insiders buying or selling AMRX?
Insider signal: Sell. Last 30 days: 0 buys, 1 sells. 258 hedge funds hold AMRX.
What is the latest news on AMRX?
Nov 3, 2026: Amneal Pharmaceuticals holds Q3 2026 earnings call · Nov 3, 2026: Amneal Pharmaceuticals releases Q3 2026 earnings, boosts yearly outlook · Nov 3, 2026: Amneal Pharmaceuticals lifts FY2026 adjusted EPS and sales guidance